Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
An open 10-day study in which the therapeutic actions of Cereton were compared with those of piracetam was performed. Cereton was used in 40 patients (experimental group) at a dose of 1000 mg, while piracetam was used in 20 patients at a dose of 2000 mg; both agents were given as intravenous infusions in 200 ml of physiological saline on the background of antiparkinsonism agents. Patients’ status was evaluated using a complex of psychometric scales and neuropsychological tests, along with tools to assess the severity of the main symptoms of parkinsonism, side effects, and quality of life. Use of Cereton produced marked and moderate improvements in the state of cognitive functions more frequently than piracetam (40% and 25%, respectively), while the incidence of deterioration was lower (5% and 15%, p < 0.05). Cereton was very well tolerated by the patients: brief and short-term side effects were seen in only six patients (15%).
- Zh. M. Glozman, Quantitative Assessment of Neuropsychological Study Data [in Russian], Moscow (1999).
- V. V. Zakharov, I. V. Damulin, and N. N. Yakhno, “Cognitive impairments in patients with Parkinson’s disease,” Zh. Nevrol. Psikhiat., 1, 13–19 (2005).
- O. S. Levin, “Mental disorders in patients with Parkinson’s disease and their correction,” in: Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 125–151.
- O. S. Levin and N. V. Fedorova, Parkinson’s Disease [in Russian], Moscow (2006).
- O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 85–91 (2008).
- I. V. Litvinenko, Parkinson’s Disease [in Russian], Moscow (2006).
- A. R. Luriya, Higher Cortical Functions in Humans and theirImpairments in Local Brain Lesions [in Russian], Moscow State University, Moscow (1969).
- A. Yu. Panasyuk, An Adapted Variant of the Wechsler Test [in Russian], Research Institute Psychiatry, Moscow (1983).
- D. Aarsland, K. Andersen, J. P. Larsen, et al., “Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study,” Arch. Neurol., 60, 387–392 (2003). CrossRef
- F. Amenta, L. Parnetti,V. Gallasi, et al., “Treatment of cognitive dysfunction associated with Alzheimer disease with cholinergic precursors,” Mech. Aging Dev., 122, 2025 (2001). CrossRef
- R. Brooks, R. Rabin, and F. de Charro, The Measurement and Valuation of Health Status Using EQ-5D, Kluwer Academic Publishers (2003).
- J. L. Cummings, “Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 76, 903–904 (2005). CrossRef
- M. Emre, D. Aarsland, A. Albanese, et al., “Rivastigmine for dementia associated with Parkinson’s disease,” New Engl. J. Med., 351, 2509–2518 (2004). CrossRef
- M. Emre, D. Aarsland, R. Brown, et al., “Clinical diagnostic criteria for dementia associated with Parkinson disease,” Mov. Dis., 22, 1689–1707 (2007). CrossRef
- S. Fahn and R. L. Elton, “Unified Rating Scale for Parkinson’s Disease,” in: Recent developments in Parkinson’s Disease, S. Fahn and C. D. Marsden (eds.), Macmillan, Florham Park, New York, pp. 153–163.
- M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental status,” J. Psychiat. Res., 12, 189–196 (1975). CrossRef
- W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 51, 745–752 (1988). CrossRef
- M. A. Hely, J. G. Morris, W. G. Reid, et al., “Sydney multicenter study of Parkinson’s disease,” Mov. Dis., 23, 837–844 (2008). CrossRef
- M. Hoehn and M. D. Jahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).
- H. Lehfeld and H. Erzigkeit, “The SKT-A Short Cognitive Performance Test for Assessing Deficits of Memory and Attention,” Int. Psychogeriat., 9, 115–121 (1997). CrossRef
- P. J. Manos and R. Wu, “The ten point clock test,” Int. J. Psych. Med., 24, 229–244 (1994). CrossRef
- L. Parnetti, F. Mignini, D. Tomasssoni, et al., “Cholinergic precursors in the treatment of cognitive impairment of vascular origin,” J. Neurol. Sci., 257, 264–269 (2007). CrossRef
- E. Perry, M. Walker, J. Grace, and R. Perry, “Acetylcholine in mind: a neurotransmitter correlate of consciousness?” Trends Neurosci., 22, 273–280 (1999). CrossRef
- S. E. Starkstein and M. Merello, Psychiatric and Cognitive Disorders in Parkinson’s Disease, Cambridge University Press, Cambridge (2002). CrossRef
- Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments
Neuroscience and Behavioral Physiology
Volume 41, Issue 1 , pp 47-51
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Parkinson’s disease
- cognitive impairments
- Cereton (choline alphoscerate)